Pemafibrate decreases triglycerides and small, dense LDL, but increases LDL-C depending on baseline triglycerides and LDL-C in type 2 diabetes patients with hypertriglyceridemia: an observational study

Table 3 Results of analyses of lipoprotein fraction and LDL-MI after pemafibrate treatment

Characteristic	Baseline			Post-dose
Characteristic	Increased LDL-C group (group I) (n = 21)	No LDL-C increase group (group NI) (n = 21)	P*	Increased LDL-C group (group I) (n = 20)	No LDL-C increase group (group NI) (n = 20)	P*
Lipoprotein fraction (PAG electrophoresis)
HDL, mean (SD), %	21.0 (7.8)	19.0 (5.2) **	0.3358	20.7 (5.6)	23.6 (5.2)	0.0907
LDL, mean (SD), %	34.2 (14.5)***	46.4 (6.5)	0.0011	47.8 (10.9)	44.9 (5.5)	0.2867
Midband, mean (SD), %	18.5 (8.5)	12.5 (6.4)	0.0141	14.7 (6.6)	14.4 (8.8)	0.9034
VLDL, mean (SD), %	28.2 (10.8) ***	22.0 (5.2) **	0.0234	17.1 (6.3)	17.3 (6.2)	0.9399
LDL-MI, median (IQR)	0.421 (0.391–0.450) ****	0.354 (0.341–0.396)	< 0.0001	0.367 (0.344–0.389)	0.348 (0.331–0.380)	0.2339

P<0.05 was considered statistically significant. *, Statistical analysis between 2 groups was done using the t-test or Mann-Whitney U test. **, P<0.02 vs. group NI at post-dose (t-test). ***, P<0.002 vs. group I at post-dose (t-test). ****, P=0.0002 vs. group I at post-dose (Mann-Whitney U test). PAG Polyacrylamide gel, LDL-MI LDL migration index, LDL-C Low density lipoprotein cholesterol, IQR Inter-quartile range, HDL High density lipoprotein, LDL Low density lipoprotein, VLDL Very-low density lipoprotein

ISSN: 1476-511X